麻豆视频

Market Trends and Insights

Rising Prevalence of Diabetes and Earlier Diagnosis

Global diabetes prevalence continues to climb, yet the more telling shift is the shorter interval between symptom onset and confirmed diagnosis.^{[1] International Diabetes Federation, “IDF Diabetes Atlas, 10th Edition,” International Diabetes Federation, idf.org} The United States now recommends HbA1c screening for every adult over 35, enlarging the pool for basal-bolus regimens that need purpose-built devices.^{[2] National Health Commission of China, “Workplace Diabetes Screening Policy Notice, January 2025,” National Health Commission, nhc.gov.cn} China mandated workplace screening for employees over 40 in January 2025, identifying millions of previously undiagnosed adults and boosting first-time device purchases. Europe recorded a 3.4% rise in pediatric type 1 incidence during 2024, lifting demand for simplified pumps with smaller reservoirs. Manufacturers are answering with color-coded pen caps and pre-set basal profiles that reduce the learning curve for new users. Earlier diagnosis therefore widens the installed base and pushes patients toward connected tools that guide dose titration.

Rapid Uptake of Connected “Smart” Pens and Add-On Caps

Smart pens that log dose data through Bluetooth or near-field communication are displacing conventional pens faster than forecast two years ago. Companion Medical’s InPen counted 180,000 active U.S. users in December 2025, up from 95,000 a year earlier.^{[3]Companion Medical, “InPen Active‐User Metrics, December 2025,” Companion Medical, companionmedical.com} The Centers for Medicare & Medicaid Services reclassified smart pens as durable medical equipment in January 2025, cutting out-of-pocket spending for Medicare Part B users. Novo Nordisk shipped 1.2 million NovoPen 6 and Echo Plus units worldwide in 2025, securing 18% of reusable-pen sales. Bigfoot Biomedical began shipping its Unity smart cap in March 2025, creating a lower-cost entry point for patients hesitant to adopt pumps. Updated IEEE 11073 standards, released in June 2025, now require end-to-end encryption, easing privacy concerns among hospital IT teams.

Reimbursement Expansion for Pen Cartridges and Patch Pumps

Payer support broadened in 2024 and 2025. Medicare removed prior-authorization barriers for patch pumps in April 2024, opening full coverage for Omnipod 5 and similar systems. Germany added connected pens to its statutory benefit catalog in January 2025 at EUR 120 per device, payable every four years. France followed in March 2025, funding smart pens when paired with continuous glucose monitors. These moves shrink out-of-pocket costs, speed adoption, and shorten payback periods for device makers. Commercial insurers in the United States are mirroring Medicare to stay competitive, lifting coverage ceilings and embracing connected hardware that may cut long-term complication costs.

Surge in GLP-1 / Insulin Co-Formulations Requiring Device Redesign

Drug pipelines now blend GLP-1 agonists with basal insulin, prompting cartridge and reservoir redesigns. Lilly’s tirzepatide-insulin glargine combo demands a larger 3 mL cartridge to handle higher viscosity. Novo Nordisk’s icodec-semaglutide pen will likely need a wider-gauge needle, a trade-off that could temper uptake among needle-averse adults. Sanofi is engineering a dual-chamber SoloStar that mixes compounds only at injection to preserve stability. Pump makers face similar tasks: Medtronic is coating reservoirs to stop protein aggregation over a three-day wear cycle. These projects delay launches by roughly one year yet remain essential because combination therapy is moving toward first-line status.

Cybersecurity and Data-Privacy Risks in Connected Pumps

Connected pumps move dose data over Bluetooth Low Energy and cellular links, creating entry points for malicious actors. The U.S. Food and Drug Administration warned in April 2024 that certain MiniMed pumps could be accessed wirelessly if older firmware remained unpatched. Insulet fixed a man-in-the-middle vulnerability in Omnipod 5 within 72 hours of discovery in June 2025, underscoring strong incident response but highlighting ongoing exposure. The European Union Medical Device Regulation now mandates a full cybersecurity risk file in conformity assessments, adding up to nine months to approval timelines. Hospitals demand ISO 27001 compliance before including connected pumps on formularies, a hurdle for smaller entrants without dedicated security teams. Persistent headline risk can slow adoption among risk-averse clinics and older patients.

Global Supply-Chain Pressure on Medical-Grade Plastics and Cannulas

Pump manufacturers rely on medical-grade polycarbonate and cyclic olefin copolymers. A 2024 fire at a Mitsubishi Chemical plant in Japan removed 22% of global cyclic olefin copolymer output, delaying new pump rollouts by up to six months. BD faced a 12-week back-order for steel cannulas in late-2024 after a labor strike in Tijuana. Polycarbonate prices rose 14% year-over-year in 2024, eroding gross margins by 150 to 200 basis points for pump makers. Insulet reduced exposure by dual-sourcing cannulas from Japan and the Philippines. Ypsomed is shifting reservoir molding to Malaysia to cut per-unit cost by 20% by mid-2026. Supply-chain diversification helps, yet material shocks remain a near-term brake on volume growth.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Insulin Delivery Devices Market Segment Analysis

Insulin pens commanded 52.44% of 2025 revenue, yet pumps are set to grow faster, with an 11.33% CAGR through 2031 as payers reward automated dosing that lowers hypoglycemia rates. Reusable pens represented 60% of pen sales, favored in regions with cartridge recycling mandates, while disposable pens held the remaining 40% thanks to convenience in markets with limited cold-chain capacity. Within pumps, tethered models still delivered 55% of 2025 pump turnover, but patch designs are advancing quickly because they avoid tubing snags and support discreet wear. Insulet shipped 1.8 million Omnipod 5 pods in 2025, up 38% year-on-year. Automated hybrid closed-loop pumps accounted for 22% of 2025 revenue share and are projected to reach 45% by 2031. Syringes continue to decline at 3% per year and now sit mainly in hospital wards and low-income regions. Needle-free jet injectors remain niche, under 2% of 2025 revenue, limited by high start-up cost and unfamiliar operation. Tandem’s Mobi pump, 50% smaller than the t:slim X2, entered the market in late-2024 and targets discretion-minded adolescents.

The U.S. Food and Drug Administration cleared the iLet Bionic Pancreas in May 2024, signaling confidence in algorithms that require minimal user input. Medtronic’s MiniMed 780G, approved in August 2024, adjusts basal rates up to 288 times per day and removes much of the carb-count burden. Chinese suppliers such as Medtrum now price starter kits at half Western levels, broadening access in middle-income economies. Reusable pens benefit from NFC-based dose logging, while disposable pens remain the default for basal-only regimens in type 2 patients who value simplicity over sustainability. Jet injectors appeal to needle-phobic adults but need stronger payer support to scale.

Conventional hardware still held 71.45% of 2025 revenue, yet connected devices will grow at a 12.77% CAGR to 2031, bolstered by payer policy that classifies smart pens as durable equipment. InPen almost doubled its active user base within a year, confirming demand for dose-memory that links to CGM trends. Tandem’s t:slim X2 and Insulet’s Omnipod 5 send basal and bolus data to cloud dashboards, enabling remote care and expanding pediatric adoption. After IEEE 11073 added encryption mandates in June 2025, hospital IT teams warmed to connected pumps.

Cost-sensitive markets still favor non-connected pens, yet add-on caps such as Bigfoot Unity provide a bridge at lower price points. Novo Nordisk’s connected pens recorded 1.2 million global shipments in 2025, equal to 18% of reusable-pen volume. As smartphone penetration widens among seniors, connected uptake should further erode the gap. However, privacy concerns and the need to update firmware will keep a role for conventional devices through the decade.

Adults drove 66.24% of 2025 revenue, reflecting the scale of type 2 diabetes, yet pediatric sales are rising faster at a 9.34% CAGR. The insulin delivery devices market size for pediatrics will surge as regulators clear closed-loop pumps for younger ages. Omnipod 5 reached children as young as two years in March 2025, answering long-held parental concerns over tubing and nighttime hypoglycemia. Tandem extended Control-IQ labeling to ages six and up in June 2024, reducing HbA1c by 1.1 percentage points without adding hypoglycemia risk.

The geriatric group held 18% of 2025 turnover and is advancing at 6.8% annually, slowed by lower tech confidence and fixed incomes. Medtronic’s simplified bolus mode reduces numeracy demands, aiding older patients. T1D Exchange data show that 42% of newly diagnosed U.S. children started on a pump in 2025 versus 28% two years earlier. Adult uptake remains moderate because entrenched injection habits and lower digital engagement persist.

Retail pharmacies still supplied 44.73% of devices in 2025, yet online channels are set to grow faster at a 12.53% CAGR as Amazon and CVS expand digital fulfillment. Amazon launched a diabetes storefront in March 2024 with next-day delivery on pen needles and infusion sets. CVS added same-day delivery for pump consumables in 47 metropolitan areas by mid-2025. Hospital pharmacies remain important in acute care and accounted for 28% of 2025 volume. Diabetes clinics combined sales with education but fell to 12% of revenue as virtual onboarding gained traction.

Walgreens announced 150 store closures in April 2025 after device footfall shifted online. Retail outlets still offer immediate counseling, but telehealth plus fast shipping is narrowing that edge. Online players benefit from bulk procurement and lower overhead, translating into lower copays. Hospitals are under pressure to prescribe take-home devices that align with patients’ home routines, further channeling sales toward retail and online platforms.

Homecare generated 43.67% of 2025 turnover and will expand at a 10.45% CAGR through 2031 as patients prefer managing therapy at home. A 2024 survey found 78% of U.S. pump users favor self-care without routine clinic visits. Hospitals and specialty clinics supplied 38% of 2025 revenue, anchored in complex cases like pediatric initiations. Ambulatory surgery centers added 12% of revenue and are rising as diabetes-related procedures move outpatient.

Medicare introduced CPT codes 99457 and 99458 in January 2024, paying doctors for remote review of device data, which incentivizes connected pump prescriptions. Hospitals aim to discharge patients on the same device they will use at home, promoting pen or patch pump adoption. Surgical centers now rely on continuous glucose monitors and automated pumps to maintain safe glucose during procedures, cutting infection rates by 18%. Homecare uptake will continue as telehealth visits replace in-person check-ups.

Geography Analysis

North America Insulin Delivery Devices Market

North America is expected to record the highest regional growth at a 9.05% CAGR through 2031 on the back of high pump penetration and broad reimbursement. Medicare’s 2024 decision to cover tubeless pumps removed historic delays in the 65-plus cohort. Canada added connected pens to provincial formularies in 2025, lifting smart-pen prescriptions by 52%. Mexico’s social-security system started funding patch pumps in February 2025, though supply constraints limited early uptake. U.S. pump penetration in type 1 diabetes reached 63% in 2025; growth now leans on type 2 patients.

Europe Insulin Delivery Devices Market

Europe held roughly 28% of 2025 turnover. Germany funded connected pens at EUR 120 per unit starting January 2025. France reimburses smart pens when paired with CGM, lowering hypoglycemia events by 28%. The United Kingdom signed a GBP 180 million framework with Medtronic and Insulet in June 2024 to deploy 100,000 hybrid closed-loop pumps by 2026. Southern Europe trails due to mixed reimbursement, while Eastern Europe still favors disposable pens. Ypsomed’s alliance with Biocon is beginning to change that dynamic.

APAC Insulin Delivery Devices Market

Asia-Pacific accounted for 38.55% of 2025 revenue, supported by expanding reimbursement and rapid uptake of lower-cost patch pumps. China now reimburses up to 70% of pump cost for urban employees, driving 200,000 Medtrum shipments in 2025. India’s Ayushman Bharat pilot covers pumps in five states but faces clinician shortages. Japan approved Terumo’s dose-memory pen in April 2024 to serve 11 million diabetics who mainly use pens. South Korea added hybrid closed-loop systems to its insurance catalog in August 2024, spurring 41% pump growth. Southeast Asia remains syringe-heavy, yet online pharmacies are improving pen access in urban areas.

MEA and South America Insulin Delivery Devices Market

Middle East and Africa plus South America combined for about 10% of 2025 turnover. Gulf states now fund patch pumps for citizens, with Saudi Arabia approving reimbursement in March 2025. South Africa’s private plans cover pumps, but public patients rely on syringes. Brazil began a pen pilot in two major cities in mid-2025 that could reach 16 million users by 2028. Argentina’s currency devaluation lifted import prices, forcing many patients back to syringes. Sub-Saharan Africa faces cold-chain gaps that restrict cartridge distribution.

Regulatory Landscape

Insulin delivery devices are regulated as medical devices and, in many cases, as drug-device combination products, which elevates design-control, human factors, and post-market obligations. In the United States, interoperable insulin pumps are regulated as ACE insulin pumps (21 CFR 880.5730, product code QFG), while interoperable glycemic controllers follow special controls under 21 CFR 862.1356, reinforcing validation of software, connectivity, and device-to-device communication used in automated insulin delivery systems. The FDA also transitioned quality requirements through the Quality Management System Regulation (QMSR), effective February 2, 2026, aligning device quality-system expectations with ISO 13485 and raising the compliance bar for manufacturers and key suppliers supporting global distribution.

In Europe, integral drug-device combinations must comply with EU pharmaceutical legislation and also meet the Medical Devices Regulation (MDR 2017/745) General Safety and Performance Requirements, with Article 117 linking the medicinal product dossier to a device conformity assessment pathway. Across regions, consensus standards influence design and verification for injection systems, with ISO 11608-1:2022 commonly referenced for dose accuracy and performance in needle-based injection systems. Cybersecurity and software controls are increasingly visible in regulatory actions, with software-related field actions such as the Omnipod 5 iOS app Class 2 recall (initiated in 2025) illustrating how connected insulin delivery ecosystems face ongoing compliance scrutiny beyond initial approvals.

Value Chain Analysis

The value chain spans upstream materials and precision components (medical-grade plastics such as polycarbonate and cyclic olefin copolymers, steel cannulas/needles, adhesives, electronics and batteries for connected pens and pumps), midstream device manufacturing (molding, assembly, software verification, and sterile/clean manufacturing for infusion set components), and downstream channels (hospital, retail, and online pharmacies plus diabetes clinics). For many suppliers and OEMs, quality-system integration is central because insulin delivery devices are frequently regulated as combination products or interoperable systems, requiring synchronized design controls, risk management, and traceability across hardware, firmware, apps, and consumables.

The chain has remained sensitive to supply shocks in critical inputs and qualified capacity. The report context highlights resin and cannula disruptions in 2024 (including a cyclic olefin copolymer capacity hit and cannula back-orders), and manufacturers responded with dual-sourcing and regional footprint shifts, such as Insulet dual-sourcing cannulas and Ypsomed shifting reservoir molding to Malaysia to reduce cost and improve continuity. On the downstream side, reimbursement expansion and remote monitoring codes have increased the operational importance of distributors and digital fulfillment, with device makers supporting onboarding, training, and cloud-based data services as part of the commercial bundle rather than treating distribution as a pure logistics step.

Market Opportunities and Future Outlook

Clinical guidance, reimbursement, and regulatory pathways are reinforcing a shift toward automated and connected insulin delivery, creating whitespace for interoperable systems, caregiver-friendly workflows, and cybersecurity-by-design updates that shorten time-to-formulary adoption. The American Diabetes Association 2026 Standards of Care designated automated insulin delivery systems as the preferred delivery approach for people with type 1 diabetes and intensive insulin-treated type 2 diabetes, which supports broader clinical uptake where coverage and training infrastructure exist. Regulatory and labeling expansion also broadens addressable segments: in June 2026 Tandem Diabetes Care received CE mark coverage for its automated insulin delivery systems in adults with type 2 diabetes and for use in type 1 diabetes during pregnancy, while FDA clearances and classifications for interoperable pumps and controllers support multi-vendor ecosystems rather than closed, single-brand stacks.

Supply availability and unit economics remain a tangible opportunity area, particularly for patch pumps and their consumables where scaling manufacturing can relieve bottlenecks and accelerate payer contracting. In May 2026, ViCentra began commercial-scale production of Kaleido patch pump consumables at Phillips Medisize, tripling capacity to support more than 17,000 users, and in June 2026 Novo Nordisk announced a 200 million yuan investment at its Tianjin, China base to expand injection device and insulin pen manufacturing. Portfolio transitions and redesign requirements around newer therapies (including GLP-1/insulin combinations) also open near-term demand for redesigned cartridges, needles, and reservoirs, favoring manufacturers that can execute device changes alongside regulatory documentation and digital feature updates without supply interruptions.